Carna Biosciences, Inc. (4572) Other
Market cap
¥7.4B
P/E ratio
-3.5x
Karna Bioscience develops kinase inhibitor drugs and provides drug discovery support services to pharmaceutical companies and research institutions.
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Return on Assets | - | - | - | - | 25.7 | -4.5 | -9.6 | -19.6 | 23.2 | -9 | 12.5 | -11.4 | 1.8 | -16.6 | -28.6 |
| Return on equity (%) | - | - | - | ||||||||||||
| Employees | 51 | 52 | 52 | 49 | 51 | 60 | 61 | 62 | 63 | 64 | 64 | 65 | 67 | 63 | 61 |